A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With Urothelial Carcinoma (KEYMAKER-U04): Master Protocol
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
University of Colorado Hospital
Principal Investigator
![Photograph of Thomas Flaig](https://som.ucdenver.edu/FIMS/Content/faculty/9411/CU-Doctors-9411.jpg)
Thomas Flaig
Study ID
Protocol Number: 22-2055
More information available at ClinicalTrials.gov: NCT00000000
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers